Vascular disrupting agents: A delicate balance between efficacy and side effects

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 305-315

  Hollebecque, Antoine ^a   Massard, Christophe ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

angiogenesis; cardiovascular toxicity; flavonoids; tubulin binding agents; vascular disrupting agent

Indexed keywords

ANTINEOPLASTIC AGENT; BNC 105 P; COMBRETASTATIN A1 PHOSPHATE; CROLIBULIN; DENIBULIN; DOLASTATIN 10; LEXIBULIN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; OMBRABULIN; PACLITAXEL; PLINABULIN; SOBLIDOTIN; UNCLASSIFIED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT; VERUBULIN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ATAXIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PAIN; CARDIOTOXICITY; CONFUSION; CORONARY ARTERY SPASM; DIZZINESS; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MOTOR NEUROPATHY; NEUROLOGIC DISEASE; NEUROTOXICITY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; SLURRED SPEECH; SOLID TUMOR; STOMATITIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; TUMOR VASCULARIZATION; URINE INCONTINENCE; VERTIGO; VISUAL DISORDER;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; SARCOMA; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84859824692     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835249de     Document Type: Review

References (74)

1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986; 46:467-473. (Pubitemid 16145386)
2. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10:417-427.
3. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9:790-803.
4. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 2011; 37:63-74.
5. Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or antiangiogenesis treatment. Int J Radiat Oncol Biol Phys 2001; 49:443-450. (Pubitemid 32120242)
6. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8:1974-1983. (Pubitemid 34633761)
7. Rustin GJS, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4- acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003; 88:1160-1167. (Pubitemid 36606327)
8. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003; 88:1844-1850. (Pubitemid 36829657)
9. Daga H, Hida T, Ishikawa S, et al. The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m2) in Japanese patients with advanced or recurrent solid tumors. Jpn J Clin Oncol 2011; 41:1067-1073.
10. Hida T, Tamiya M, Nishio M, et al. Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with nonsmall cell lung cancer. Cancer Sci 2011; 102:845-851.
11. Dowlati A, Robertson K, Cooney M, et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62:3408-3416. (Pubitemid 34651387)
12. Rustin GJS, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21:2815-2822. (Pubitemid 46621828)
13. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428-4438. (Pubitemid 46621821)
14. He X, Li S, Huang H, et al. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. Br J Clin Pharmacol 2011; 71:860-870.
15. Bilenker JH, Flaherty KT, Rosen M, et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005; 11:1527-1533. (Pubitemid 40315236)
16. Rustin GJ, Shreeves G, Nathan PD, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102:1355-1360.
17. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors [ASCO Meeting Abstracts]. J Clin Oncol 2008; 26 (15 Suppl): 3550.
18. Ng QS, Mandeville H, Goh V, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with nonsmall-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 2012; 23:231-237.
19. Meyer T, Gaya AM, Dancey G, et al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 2009; 15:4484-4492.
20. Sessa C, Soria J, Tolcher A, et al. A phase I pharmacokinetic and pharmacodynamic study of AVE8062 in patients with advanced solid tumors. Ann Oncol 2009; 20 (Suppl 3):iii24.
21. Tresca P, Tosi D, Van Doorn L, et al. Phase I and pharmacologic study of the vascular disrupting agent ombrabulin combined with docetaxel in patients with advanced solid tumors [ASCO Meeting Abstracts]. J Clin Oncol 2010; 28 (15 Suppl):3023.
22. Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006; 12:2834-2840.
23. Michels JE, Ellard S, Le L, et al. A phase I study of ABT-751 in combination with docetaxel in patients with metastatic hormone-refractory prostate cancer [ASCO Meeting Abstracts]. J Clin Oncol 2006; 24 (18 Suppl):4651.
24. Rudin CM, Mauer A, Smakal M, et al. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2011; 29:1075-1082.
25. Mita MM, Spear MA, Yee LK, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res 2010; 16:5892-5899.
26. Millward M, Mainwaring P, Mita A, et al. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs 2011. [Epub ahead of print]
27. Pitot HC, Mcelroy EA, Reid JM, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999; 10:525-531. (Pubitemid 29131961)
28. Tsimberidou AM, Akerley W, Schabel MC, et al. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther 2010; 9:3410-3419.
29. Grossmann KF, Ward JH, Akerley WL, et al. A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme [ASCO Meeting Abstracts]. J Clin Oncol 2010; 28 (15 Suppl):2095.
30. Hwu W, Akerley WL, Stephenson J, et al. Final report: combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma [ASCO Meeting Abstracts]. J Clin Oncol 2010; 28 (15 Suppl): 8531.
31. Lickliter JD, Francesconi AB, Smith G, et al. Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Br J Cancer 2010; 103:597-606.
32. Francesconi A, Kotasek D, Burge M, et al. Phase I evaluation of orallyadministered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer [ASCO Meeting Abstracts]. J Clin Oncol 2009; 27 (15S):3568.
33. Lickliter J, Fida R, Wheeler H, et al. Carboplatin combined with the vasculardisrupting agent CYT997 for recurrent glioblastoma multiforme [ASCO Meeting Abstracts]. J Clin Oncol 2010; 28 (15 Suppl):e13591.
34. Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-h intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004; 15:671-679. (Pubitemid 38559607)
35. de Jonge MJ, Van der Gaast A, Planting AST, et al. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 2005; 11:3806-3813. (Pubitemid 40685600)
36. Greystoke A, Blagden S, Thomas AL, et al. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 2006; 17:1313-1319. (Pubitemid 44288224)
37. Tamura K, Nakagawa K, Kurata T, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 2007; 60:285-293. (Pubitemid 46742544)
38. Horti J, Juhasz E, Monostori Z, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with nonsmall cell lung cancer. Cancer Chemother Pharmacol 2008; 62:173-180.
39. Yamamoto N, Andoh M, Kawahara M, et al. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci 2009; 100:316-321.
40. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006; 24:1491-1498. (Pubitemid 46638769)
41. LoRusso PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008; 26:159-167.
42. Rischin D, Bibby DC, Chong G, et al. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res 2011; 17:5152-5160.
43. Anthony SP, Von Hoff D, Whisnant JK, et al. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition [ASCO Meeting Abstracts]. J Clin Oncol 2007; 25 (18 Suppl):14043.
44. Read WL, Rosen P, Lee P, et al. Pharmacokinetic and pharmacodynamic results of a 4-hr IV administration phase I study with EPC2407, a novel vascular disrupting agent [ASCO Meeting Abstracts]. J Clin Oncol 2009; 27 (15S):3569.
45. Ricart A, Ashton E, Cooney M, et al. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68:959-970.
46. Traynor AM, Gordon MS, Alberti D, et al. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest New Drugs 2010; 28:509-515.
47. Patterson DM, Zweifel M, Middleton MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 2012. [Epub ahead of print]
48. Lara PN, Douillard JY, Nakagawa K, et al. Randomized phase III placebocontrolled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:2965-2971.
49. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced nonsmall cell lung cancer. Br J Cancer 2008; 99:2006-2012.
50. Pili R, Rosenthal MA, Mainwaring PN, et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010; 16:2906-2914.
51. Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial [ASCO Meeting Abstracts]. J Clin Oncol 2011; 29 (15 Suppl):5502.
52. Garon EB, Kabbinavar FF, Neidhart JA, et al. A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous nonsmall cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial [ASCO Meeting Abstracts]. J Clin Oncol 2011; 29 (15 Suppl):7559.
53. Mita AC, Heist RS, Aren O, et al. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with nonsmall cell lung cancer (NSCLC) [ASCO Meeting Abstracts]. J Clin Oncol 2010; 28 (15 Suppl):7592.
54. McKeage MJ, Fong P, Jeffery M, et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006; 12:1776-1784.
55. Li J, Jameson MB, Baguley BC, et al. Population pharmacokinetic- pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4- acetic acid in cancer patients. Clin Cancer Res 2008; 14:2102-2110. (Pubitemid 351551122)
56. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003; 89:1334-1344. (Pubitemid 37363426)
57. Kim LJ, Chamberlain MC, Zhu J, et al. Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naive to treatment with bevacizumab [ASCO Meeting Abstracts]. J Clin Oncol 2011; 29 (15 Suppl):2088.
58. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008; 43:100-111.
59. Chebil M, Soria J, Chami L, et al. Interest of DCE-US with quantification to demonstrate the VDA effect on vascularization in patients with advanced solid tumors treated with AVE8062 [ASCO Meeting Abstracts]. J Clin Oncol 2009; 27 (15S):e14522.
60. O'Connor JPB, Jackson A, Parker GJM, et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96:189-195. (Pubitemid 46160619)
61. Galbraith SM. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002; 20:3826-3840.
62. Galbraith SM,Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21:2831-2842. (Pubitemid 46621830)
63. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10:3650-3657. (Pubitemid 38697598)
64. Mutin M, Canavy I, Blann A, et al. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93:2951-2958. (Pubitemid 29200786)
65. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7:101-111. (Pubitemid 40126386)
66. Farace F, Massard C, Borghi E, et al. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 2007; 18:1421-1422. (Pubitemid 47305018)
67. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59:1626-1634. (Pubitemid 29160136)
68. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5:423-435. (Pubitemid 40791485)
69. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990; 50:4478-4484. (Pubitemid 20230379)
70. Bertelsen LB, Shen YY, Nielsen T, et al. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int J Radiat Oncol Biol Phys 2011; 87:1126-1134.
71. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 [Internet]. Int J Radiat Oncol Biol Phys 2002; 53:164-171. (Pubitemid 34465821)
72. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66:11520-11539. (Pubitemid 46094158)
73. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313:1785-1787. (Pubitemid 44454154)
74. Welford AF, Biziato D, Coffelt SB, et al. Brief report TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011; 121:1969-1973.